Wize Pharma (Israel) Buy Hold or Sell Recommendation

    WIZP -- Israel Stock  

    ILS 213.00  10.20  5.03%

    Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Wize Pharma is 'Not Rated'. Macroaxis provides Wize Pharma buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding WIZP positions. The advice algorithm takes into account all of Wize Pharma available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from WIZP buy-and-hold prospective. See also Your Current Watchlist.

    Time Horizon

    Risk Tolerance

    Execute Advice
    Sell Wize PharmaBuy Wize Pharma
    Not Rated
    For the selected time horizon Wize Pharma has a risk adjusted performance of 0.1955, jensen alpha of 39.44, total risk alpha of 77.3, sortino ratio of 0.0 and treynor ratio of (0.68)
    Macroaxis provides buy or sell recommendation on Wize Pharma to complement and cross-verify current analyst consensus on Wize Pharma. Our buy or sell advice engine determines the company potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. Use Wize Pharma Price to Book, Net Income and the relationship between Shares Outstanding and EBITDA to make sure your buy or sell decision on Wize Pharma is adequate.

    Wize Pharma Returns Distribution Density

    Mean Return47.60Value At Risk0.00
    Potential Upside0.00Standard Deviation21,300
     Return Density 

    Wize Pharma Alerts

    Trading Alerts and Improvement Suggestions

    Wize Pharma is not yet fully synchronised with the market data
    Wize Pharma generates negative expected return over the last 30 days
    Wize Pharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
    The company has accumulated 707K in total debt with debt to equity ratio (D/E) of 217.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Wize Pharma has Current Ratio of 0.23 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
    This company reported revenue of . Net Loss for the year was (1.91M).
    WIZE PHARMA has accumulated about 275K in cash with (1.1M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
    See also Your Current Watchlist. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
    Search macroaxis.com